Immunocore Executive David Berman to Leave Company in 2026
Immunocore Holdings announced that Dr. David Berman, Executive Vice President, EVP, Research and Development, will leave the Company effective 27 February 2026. Dr. Berman has accepted a Development Head role at a large commercial-stage biotech company. Immunocore does not intend to seek a direct replacement for Dr. Berman and will instead streamline its R&D structure and leverage the existing experienced leadership team. The Company is promoting Dr. Mohammed Dar, its current Chief Medical Officer, and Mark Moyer, its current Head of Regulatory Sciences, to Executive Vice President roles, assuming expanded oversight of clinical development and regulatory strategies.
Trade with 70% Backtested Accuracy
Analyst Views on IMCR
About IMCR
About the author
Immunocore Announces R&D Leadership Changes
- Executive Departure: Immunocore announced that Executive Vice President of R&D David Berman will leave the company on February 27, 2026, to take a role at another biotech firm, indicating a significant leadership transition for the company.
- Internal Promotions: The company is promoting current Chief Medical Officer Mohammed Dar and Head of Regulatory Sciences Mark Moyer to Executive Vice President roles, with expanded responsibilities for clinical development and regulatory strategies, aiming to enhance R&D efficiency by leveraging the existing leadership team.
- R&D Achievements: Dar has led clinical development since 2019, successfully advancing KIMMTRAK to regulatory approval, which is now approved in 39 countries, showcasing the company's strong capabilities in oncology immunotherapy.
- Strategic Commitment: CEO Bahija Jallal expressed confidence in the R&D team despite the executive changes, committing to continue advancing clinical programs to meet patient needs for transformative therapies.
Immunocore to Showcase at Upcoming Investor Events
Company Overview: Immunocore Holdings plc is a biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, utilizing its ImmTAX platform for TCR bispecific immunotherapies.
Upcoming Conferences: The company will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11, 2025, and the Jefferies London Healthcare Conference on November 19, 2025, with live webcasts available on their website.
Product Highlight: Immunocore's leading oncology therapy, KIMMTRAK, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several countries, including the US and EU.
Contact Information: For inquiries, Immunocore provides contact details for communications and investor relations, including email addresses and phone numbers.